Radimmune Therapeutics
Albany
About Radimmune Therapeutics
Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary antibodies targeting extracellular accumulations of, normally, intracellular substances. Since its inception, the Radimmune Therapeutics has been driven by the belief that additional tools are needed for the fight against cancer. To that end, Radimmune Therapeutics has developed proprietary technology and platform focused on the most challenging to treat cancers. It is based in Burlingame, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $13.6M
- Last round: Series Unknown (Aug 2019)
- Website: radimmune.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Therapeutics
Canonical: https://fsome.com/organization/radimmune-therapeutics-104620 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.